Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposome bupivacaine
- Development stage
- Approved
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Percutaneous, Parenteral
01
Overview
Liposome bupivacaine is an extended-release formulation of the amide-type local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. It utilizes the proprietary DepoFoam technology, which consists of multivesicular liposomes that encapsulate the drug and release it slowly over time, typically extending the duration of pain relief up to 72 hours. This formulation is primarily indicated for single-dose infiltration into the surgical site or for use in specific regional nerve blocks, such as interscalene brachial plexus blocks or sciatic nerve blocks, to manage postoperative pain while reducing the need for systemic opioids. Developed by Pacira BioSciences, it is marketed under the brand name Exparel and has been extensively studied in various surgical procedures, including total knee arthroplasty and bunionectomy.
- Brand names
- Exparel
- Other names
- liposome bupivacaineliposomal bupivacainebupivacaine liposome injectable suspension
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)SCN5A (Sodium channel protein type 5 subunit alpha)CaV (Voltage-gated calcium channel protein complex)Kir (Inward-rectifier potassium channels)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on liposome bupivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposome bupivacaine.